Dogwood Therapeutics Retained Earnings (Accumulated Deficit) 2020-2024 | DWTX

Dogwood Therapeutics retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Dogwood Therapeutics Retained Earnings (Accumulated Deficit) 2020-2024 | DWTX

Dogwood Therapeutics retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.7B
Vertex Pharmaceuticals (VRTX)$125B
Regeneron Pharmaceuticals (REGN)$112.1B
Bristol Myers Squibb (BMY)$107B
Gilead Sciences (GILD)$106.8B
CSL (CSLLY)$97.4B
GSK (GSK)$80.7B
Alnylam Pharmaceuticals (ALNY)$36.9B
Argenex SE (ARGX)$32.6B
BioNTech SE (BNTX)$27.9B
Biogen (BIIB)$27.9B
Illumina (ILMN)$23.5B
Moderna (MRNA)$22B
BeiGene (BGNE)$21.7B
Genmab (GMAB)$15.3B
BioMarin Pharmaceutical (BMRN)$13.4B
Exact Sciences (EXAS)$12.9B
Vaxcyte (PCVX)$12.9B
Insmed (INSM)$12.8B
Incyte (INCY)$12.8B
Sarepta Therapeutics (SRPT)$11.8B
Bio-Techne Corp (TECH)$11.7B
QIAGEN (QGEN)$10B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.8B
Legend Biotech (LEGN)$8.2B
Revolution Medicines (RVMD)$8.2B
Exelixis (EXEL)$8.1B
Repligen (RGEN)$8.1B
Intra-Cellular Therapies (ITCI)$7.9B